Form 4: Integra LifeSciences Director Shaundra Clay Reports Acquisition and Disposal of Common Stock

Director Shaundra Clay reports acquiring 19,592 shares of Integra LifeSciences common stock and disposing of 41,515 shares in a recent transaction.

Summary

• On May 9, 2025, Shaundra Clay, a director of Integra LifeSciences Holdings Corp, reported a transaction involving the company's common stock.
• Clay acquired 19,592 shares of common stock.
• Simultaneously, Clay disposed of 41,515 shares of common stock.
• Following these transactions, Clay beneficially owns 41,515 shares of Integra LifeSciences.
• Clay has granted Lesha Shinn, Chantal Veillon, and John Siemann power of attorney to handle SEC filings related to Integra LifeSciences.
• This power of attorney includes the ability to file forms, schedules, and other documents with the SEC, including Forms 3, 4, and 5, as well as Schedules 13D and 13G.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a transaction by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and major shareholders) to report transactions in their company's stock, providing transparency to the market.

Stakeholder Impact

• The transaction could influence investor perception of the company, depending on the size and nature of the transaction.

Key Dates

Keywords

Form 4, Integra LifeSciences, Director, Shaundra Clay, Beneficial Ownership, SEC Filing, Power of Attorney, Stock Transaction